SOT for Cancer, Lyme, Co-Infections and Viruses

---

Supportive Oligonucleotide Therapy (SOT) is a treatment for infections and cancer. The treatments are made from the patients’ blood and therefore are tailored to each patient. By silencing a critical gene of the infectious agent, or cancer cell, it is able to kill them.

Research Genetic Cancer Center (RGCC), a medical genetics company in Greece, has done a lot of work to enhance SOT. SOT started at RGCC labs almost 10 years ago. SOT is also known as Antisense Oligodeoxynucleotide Therapy (AOT). SOT is based on many years of research by European and American companies and universities.

SOT blocks the function of a critical gene. Nucleotides are the building blocks of DNA and RNA. “Oligo” means “few”. Oligonucleotides consist of a sequence of nucleotides rarely more than 20 bases long. The term “antisense” oligodeoxynucleotide refers to the fact that it is designed to bind to complementary RNA bases in the target cell.

A mRNA molecule that is bound to an antisense strand of messenger RNA cannot bind to the ribosome and therefore its protein cannot be made. This makes the target gene nonfunctional. Blocking the function of a critical gene causes the cell to die.

It is a small oligodeoxynucleotide which is complementary to a sequence of nucleotides. SOT kills a cancer cell by targeting a gene which is responsible for anti-apoptotic signals. Each individual gene is related to anti-apoptotic signals inside cancer cells. Apoptosis is programmed cell death. The SOT molecule blocks the expression which encodes a protein with anti-apoptotic effect.

RGCC has state-of-the-art equipment and technology which enables them to identify specific gene sequences of various infectious agents and cancer cells. The patient’s blood is drawn at our clinic to obtain the pathogens and circulating cancer stem cells (CSCs). RGCC is able to identify the main gene epitope (gene sequence) of the target genes and to create the SOT. RGCC’s unique verification process includes cross-referencing the main gene sequences with the information stored in an international genetics database. This makes it possible to have the most accurate SOT and to maximize the success of treatment. SOT does not interfere with the functioning of normal human cells, tissues, or organs. The term “sense strand” refers to the replication genes, the genes that cause cell replication. Once these genes are identified, RGCC creates an anti-copy, or antisense strand, of the replication sequences of the translocation genes. This anti-copy is a complementary copy of the DNA sequences that codes for replication.

RGCC Labs uses miRNA (micro RNAs) to influence only certain gene expressions and not to change genetic structure.

Subsequently, this anti-copy is surrounded with a synthetic messenger RNA (mRNA) to enable it to penetrate the target’s cell wall. Next, this mRNA is replicated to ~500 million to 1 billion copies of SOT molecules. Finally, RGCC ships the SOT to the doctor’s office where it will be administered to the patient. After the intravenous infusion, the SOT molecules will work around the clock for about six months.

Follow-up testing is strongly recommended to see when the virus/Lyme infection is resolved and, in cancer, to confirm the amount of cancer stem cells (CSCs) decreasing.

A unique SOT is needed for each infection. Patients with multiple infections will need more than one SOT. Usually only one treatment is needed per infection. Occasionally a second SOT, for the same infection, is required. In this case the second SOT is administered about 6 months later.

SOT is not an immune treatment because it does not modulate the immune system. Side effects are usually minimal and may include headaches, body aches, general malaise, sweating, diarrhea, cough, and fever. Usually, these symptoms resolve within 24-48 hours.

Caution is needed in patients with a large tumor burden. SOT induces rapid apoptosis in circulating tumor cells (CTCs), circulating cancer stem cells, primary tumor cells, and metastatic tumors. In addition, it is able to cross the blood-brain barrier. The doctor may recommend a PET/CT, CT, or MRI scan prior to the SOT to assess tumor burden. Cancer with metastasis could result in Tumor Lysis Syndrome (TLS), which can be life-threatening.

Currently, the SOT is available for the following Lyme species and co-infections: 

Babesia odocoilei

Babesia microti 

Babesia bigemina 

Babesia divergens 

Babesia duncani 

Babesia bovis 

Bartonella henselae 

Bartonella bacilliformis 

Bartonella vinsonii 

Bartonella quintana 

Bartonella eluzabethae 

Borrelia mayonii 

Borrelia burgdorferi 

Borrelia garinii 

Borrelia bissettii 

Borrelia bavariensis 

Borrelia miyamotoi 

Borrelia valaisiana 

Borrelia afzelii 

Borrelia finlandensis 

Borrelia recurrentis 

Borrelia valaisiana 

Borrelia hermsii 

Borrelia lusitaniae 

Borrelia sinica 

Borrelia kurttenbachii 

Borrelia genomospecies 

Borrelia turcica   

Borrelia turicatae 

Borrelia miyamotoi

Borellia californiensis 

Candidatus Borrelia 

Candidatus Borrelia tachyglossi

Anaplasma  phacocytophilum  

Ricketsia rickettsi  

Enrlichia chaffeensis

and for the following viruses:

EBV (Epstein Barr Virus)
CMV (cytomegalovirus)

Coxsackie virus (Types A & B)

VZV (Varicella Zoster virus (chicken pox, shingles))

HHV1/HSV1 (oral herpes virus)

HHV2/HSV2 (genital herpes virus)

HHV6 (Types A & B) (human herpes virus 6)

HPV (16/18) (human papillomavirus)

HPV (6/11) (human papillomavirus)

HTLV1 (Human T-cell lymphotropic Virus)
HBV (Hepatitis B Virus)
HCV (Hepatitis C Virus)

HIV (Human Immunodeficiency Virus)

SOT terminates its gene replication sequences, thus eliminating the next lifecycle and eradicating it from the body. If a patient has multiple active infections, then multiple SOT treatments will be needed for each infection. 

SOT is not an immune treatment, because it does not work by modulating the immune system. Because it is highly compatible with the patient, the side effects are usually minimal. Potential side effects may include headaches, body aches, general malaise, sweating, diarrhea, cough, fever, (generally <=101°F), and mild to moderate flulike symptoms. Usually, these symptoms resolve within 24-48 hours or a week at most.

SOT for Cancer: SOT induces rapid apoptosis in circulating tumor cells (CTCs), circulating cancer stem cells (CSCs), primary tumor cells, and metastatic tumors. In addition, it is able to cross the blood-brain barrier. As it penetrates into these cells it will interfere with their ability to replicate. The doctor  will  recommend a PET/CT, CT, or MRI scan prior to the SOT to assess the patient’s cancer for any metastasis. To reduce the risk of mild to severe adverse reactions, and to adjust the SOT dosing and timing, according to each individual case. Cancer with metastasis could result in Tumor Lysis Syndrome (TLS), which can be life threatening.